![Yvonne McGrath](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Yvonne McGrath
Direttore Tecnico/Scientifico/R&S presso ITEOS THERAPEUTICS, INC.
Patrimonio netto: 460 040 $ in data 30/06/2024
Posizioni attive di Yvonne McGrath
Società | Posizione | Inizio | Fine |
---|---|---|---|
ITEOS THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 01/05/2020 | - |
Storia della carriera di Yvonne McGrath
Precedenti posizioni note di Yvonne McGrath
Società | Posizione | Inizio | Fine |
---|---|---|---|
Complix NV
![]() Complix NV Pharmaceuticals: MajorHealth Technology Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium. | Direttore/Membro del Consiglio | 01/05/2014 | 01/04/2020 |
Direttore Tecnico/Scientifico/R&S | 01/05/2014 | 01/04/2020 | |
IMMUNOCORE HOLDINGS PLC | Corporate Officer/Principal | 01/01/2010 | 01/04/2014 |
Immunocore Ltd.
![]() Immunocore Ltd. Pharmaceuticals: MajorHealth Technology Part of Immunocore Holdings Plc, Immunocore Ltd. is a British commercial-stage biotechnology company that develops and commercializes transformative medicines to address unmet needs in cancer, infection, and autoimmune disease. The company is based in Oxon, UK. The company has a robust pipeline of wholly owned and partnered programs to address a broad spectrum of disease indications, built on their proprietary soluble TCR bi-specific Immtac® platform. The company was founded in 2007, and the CEO is Bahija Jallal. | Corporate Officer/Principal | 01/01/2010 | 01/04/2014 |
Formazione di Yvonne McGrath
Queen’S University Belfast | Undergraduate Degree |
Cardiff University School of Medicine | Doctorate Degree |
Statistiche
Distribuzione geografica
Regno Unito | 5 |
Belgio | 2 |
Stati Uniti | 2 |
Posizioni
Corporate Officer/Principal | 2 |
Chief Tech/Sci/R&D Officer | 2 |
Director/Board Member | 1 |
Settori
Health Technology | 5 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
IMMUNOCORE HOLDINGS PLC | Health Technology |
ITEOS THERAPEUTICS, INC. | Health Technology |
Aziende private | 2 |
---|---|
Complix NV
![]() Complix NV Pharmaceuticals: MajorHealth Technology Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium. | Health Technology |
Immunocore Ltd.
![]() Immunocore Ltd. Pharmaceuticals: MajorHealth Technology Part of Immunocore Holdings Plc, Immunocore Ltd. is a British commercial-stage biotechnology company that develops and commercializes transformative medicines to address unmet needs in cancer, infection, and autoimmune disease. The company is based in Oxon, UK. The company has a robust pipeline of wholly owned and partnered programs to address a broad spectrum of disease indications, built on their proprietary soluble TCR bi-specific Immtac® platform. The company was founded in 2007, and the CEO is Bahija Jallal. | Health Technology |
- Borsa valori
- Insiders
- Yvonne McGrath
- Esperienza